Tag: Medi Tours germany

Dr Carl O Helvie lung cancer survivor interviews Grace Gawler on the Holistic Health show

Recently I had the pleasure of being interviewed by Dr Carl Helvie for the USA based Holistic health Show. Dr. Carl was a relatively young man when he was diagnosed with lung cancer and told he had six months to live. Instead, he made a decision to fight back with something other than the traditional conventional medicine he was offered.

Introducing Dr Carl O Helvie: Recently I had the pleasure of being interviewed by Dr Carl Helvie for the USA based Holistic Health Show. Dr. Carl was a relatively young man when he was diagnosed with lung cancer and told he had six months to live. Instead, he made a decision to fight back with something other than the traditional conventional medicine he was offered. Amongst the millions of diagnosed cancer patients, his type of total, long term remission is a rare event. When a histologically proven cancer goes into remission we must always be open to asking ‘Why’? Also in Dr Carl’s favor is that he is a well qualified, well credentialed and highly intelligent man who has dedicated his life to helping others diagnosed with cancer. Just occasionally someone comes along like Dr Carl who has managed to recover from cancer without conventional medicine. Remember the story of Deborah Franke Ogg whose stage 4 nodular lymphoma went in to remission.  (hear my interview with Deborah at Voice America

Watch the clip from the movie about her life and remission; ” Leap of Faith”  later retitled “A question of Faith”. 
http://www.samneillonline.com/leapoffaith.html

Dr Carl O Helvie at 80 years young - one of the longest living lung cancer survivors.
Dr Carl O Helvie at 80 years young – one of the longest living lung cancer survivors.

Dr Carl Helvie also has an extraordinary story. A registered nurse with two masters and a doctorate in public health and wellness, Dr. Carl Helvie has decades of experience as a nurse practitioner, educator, author and researcher. He is the recipient of numerous awards with listings in Who’s Who In American Nursing, Men of Achievement, American Men and Women of Science, just to name a few. He has eight published books as well as being a contributor to others, and has published or presented internationally over 100 papers and articles. He retired from academia in 2000 and in 2002, taught at the University of Applied Sciences in Frankfurt, Germany and served as a nursing consultant to Russia.

He developed and published a nursing theory now used worldwide and has established a nursing center that provides primary care for homeless and low-income individuals and families.
While 89% of Americans over age 65 have some form of chronic illness and by age 75 can expect to have three chronic illnesses and be taking five prescribed medications daily – Dr Carl’s prescription; today, this healthy 80-year-old man takes no prescribed medications and is one of the longest living lung cancer survivors.

Select the URL below to listen to Dr Carl as he asks me in depth questions about my life and why and how I teach survival skills for those with life challenging illness or conditions: 

http://www.holistichealthshow.com/wordpress/tag/holistic-approach/

Also listen to Navigating the cancer Maze. Today’s show is  Cancer Recovery-Crucial Choices: How to Navigate Critical Crossroads in the Cancer Maze

To read more about Dr Carl O Helvie  and his work  visit:  http://www.beatlungcancer.net/bio/

Groundbreaking Cancer Immunotherapy Grace Gawler interviews Dr Horst Lindhoffer Munich

On today’s edition of Navigating the Cancer Maze, Grace Gawler interviews Dr Horst Lindhoffer PhD about one of the most innovative and exciting cancer immunotherapy treatment breakthroughs in many years. Visit germancancertreatments.com for more information.

On Navigating the Cancer Maze – Cancer Immunotherapy – Ground-breaking treatment in Cancer Medicine Grace Gawler -August 2, 2013

 “Destroying cancer stem cells means fighting cancer at its roots”, says Horst Lindhofer, CEO of TRION Pharma. “Catumaxomab’s efficacy against this particularly aggressive and resistant population of cancer cells further supports its therapeutic potential for the treatment of EpCAM-positive carcinomas.”

On today’s edition of Navigating the Cancer Maze, I interview Dr Horst Lindhoffer PhD about one of the most innovative and exciting cancer treatment breakthroughs in many years. We know that The human immune system is usually quite effective at identifying and eliminating abnormal cells.

dr horst lindhofer
Dr Horst Lindhofer

 Cancer cells, however, can form tumors and spread throughout the body. Although chaotic in their behavior, cancer cells operate with high level intelligence to escape detection by our immune system’s control mechanisms. Often misunderstood, this is a fundamental principle in understanding how cancer cells behave and how immune recognition can be assisted. The new breakthrough cancer treatments capitalize on that information. It has been a long-standing vision of physicians and scientists to develop a treatment that can put the immune system back on track. TRION has achieved the goal with its trifunctional Triomab® antibodies. Listen to learn more or contact grace@germancancertreatments.com for further details.

Listen to this interview at:
http://www.voiceamerica.com/episode/72038/cancer-immunotherapy-ground-breaking-treatment-in-cancer-medicine
Catumaxomab (Removab®) is presently the only approved therapeutic antibody targeting EpCAM, a surface antigen that is widely expressed in the most frequent forms of human cancer. On April 20th this year, Removab® received EU approval for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. Removab® is the first product world-wide to receive a regulatory approval for this indication. With its trifunctional mode of action, Removab® represents a new generation of antibodies using the body’s own immune system to help fight the tumor cells.

For more information visit www.germancancertreatments.com Enquiries: To discover more about Horst Lindhoffer’s work with Trifunctional antibodies  – please email grace@germancancertreatments.com

EpCAM: EpCAM or epithelial cell adhesion molecule is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas, such as breast, lung, colorectal, gastric, prostate and ovarian cancer. Catumaxomab (Removab®) is the only approved anti-EpCAM antibody available.

Triomab®: Trifunctional antibodies : Triomab® antibodies bind to cancer-specific surface antigens and recruit both T cells as well as accessory cells, such as macrophages, dendritic cells and natural killer cells, to the tumor site. As a result, they provide for a new quality of cancer cell killing, activating both arms of the immune system – the adaptive one with cytotoxic T cells as effectors and the innate one including accessory effector cells.

dendritic cell image
dendritic cell image

Triomab® antibodies are therefore very effective in destroying cancer cells and show a therapeutic effect at very low doses. Triomab® antibodies are a development of TRION Pharma GmbH Catumaxomab was invented by TRION Pharma and has been developed with Fresenius Biotech.

Trifunctional Antibody Catumaxomab Triggers Vaccination Effect Against Cancer: On June 06, 2011 Munich, Germany – TRION Pharma GmbH released and announced new information – the results from two different studies demonstrating catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination.  Continue reading “Groundbreaking Cancer Immunotherapy Grace Gawler interviews Dr Horst Lindhoffer Munich”